Jobs / United States / Novartis Pharmaceuticals Corporation
Portfolio Management & LCM, Associate/ Lead/ Senior Lead
Novartis Pharmaceuticals Corporation · 🇺🇸 Toranomon (NPKK Head Office)
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 75 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Novartis Pharmaceuticals Corporation paid sponsored hires in similar roles3 certified filings for “ED, Portfolio & Early Pipeline Strategy” (Marketing Managers) in NJ: $199k–$199k, median $199k. Most were filed at wage level III (100%) — 3 lottery entries, ≈46% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Novartis Pharmaceuticals Corporation
The US Department of Labor certified 75 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Novartis Pharmaceuticals Corporation →
About the role
Job Description Summary Portfolio Management & LCM Lead The role is responsible for executing portfolio and late lifecycle management activities for assigned mature and non priority brands, ensuring disciplined budgeting, performance vigilance, and operational continuity. The position translates portfolio strategy into high quality execution, provides actionable insights, and enables informed decision making through close cross functional collaboration. Job Description Major Accountabilities Shape portfolio strategy through analytics and insight • Analyze portfolio and brand performance using market forecasts, financials, and competitive intelligence • Develop clear strategic options (e.g., invest, optimize, simplify, exit) with quantified impact and trade‑offs • Support leadership decision‑making by structuring insights into concise, decision‑ready recommendations Drive lifecycle and portfolio initiatives • Lead late‑lifecycle strategies such as SKU rationalization, pack optimization, and cost‑to‑serve improvement • Ensure initiatives are aligned with overall portfolio priorities and country commercial strategy • Track impact post‑implementation and refine recommendations based on performance Orchestrate cross‑functional collaboration within and beyond the Commercial Portfolio Unit • Work closely with Digital Marketing Execution to explore scalable, efficient execution models for assigned brands • Collaborate with Commercial Partnerships & Alliances to assess internal vs. external delivery options • Lead the structured transition and onboarding of brands from Therapeutic Areas into the Commercial Portfolio, coordinating the handover of budgets, forecasts, data, materials, and key assumptions to ensure continuity and execution readiness. Manage portfolio governance, forecasting, and performance tracking • Support budgeting and forecasting processes for assigned brands and portfolio segments • Monitor performance against targets, identify risks and opportunities, and recommend corrective actions • Contribute to portfolio reviews, governance forums, and leadership discussions Provide senior‑level contribution and informal leadership • Serve as a subject‑matter expert within the portfolio team • Provide guidance and thought leadership without formal people management responsibility • Model structured thinking, ownership, and cross‑functional collaboration Key Performance Indicators (Suggested priority KPIs * italicized ) • Accuracy and timeliness of forecasts and budget submissions. • Portfolio performance versus financial and operational targets. • Quality, frequency, and clarity of performance vigilance insights. • Timeliness and completeness of responses to ad hoc operational requests. • Effectiveness of cross‑functional collaboration based on stakeholder feedback. • Compliance with portfolio investment guardrails. Ideal Background Education: · Bachelor’s degree in business, finance, science, or related field. · Advanced degree preferred (e.g., Master of Business Administration (MBA)). Languages: · Business level English · Native level Japanese Experience/Professional Requirement: • 7–10 years of commercial or marketing experience within the pharmaceutical or medical device industry, with hands‑on ownership of brands across the end‑to‑end product lifecycle, including mature and late‑stage phases beyond launch execution. • Proven experience contributing to or leading portfolio level strategy, looking beyond individual brands to optimize, reprioritize, or revise lifecycle strategies, with particular focus on late stage value maximization and portfolio trade offs. • Strong capability in leveraging analytics, market for